Fibrinolytic therapy involves the use of thrombolytic drugs or clot-busting drugs to dissolve blood clots (fibrin) in arteries and veins. Fibrinolytic drugs help restore flow in arteries and veins narrowed or blocked by a blood clot. These drugs are usually used to treat pulmonary embolism, deep vein thrombosis, and arterial thrombosis.

Market key trends:

One of the major market trends fueling the growth of the fibrinolytic therapy market is the rising incidences of cardiovascular diseases globally. According to the World Health Organization (WHO), cardiovascular diseases are the largest cause of deaths globally, accounting for over 17.9 million deaths per year. The increasing prevalence of cardiovascular disorders is expected to propel the demand for fibrinolytic drugs for treatment. In addition, the rising geriatric population is also contributing to the market growth. Older adults are more susceptible to developing cardiovascular diseases, thus driving the need for fibrinolytic therapy. Furthermore, ongoing technological advancements in thrombolytic therapy and the development of novel agents are expected to present lucrative growth opportunities for players in the fibrinolytic therapy market over the forecast period.

Porter’s Analysis

Threat of new entrants: The threat of new entrants in the Fibrinolytic Therapy Market Size is low, owing to the high capital investments required and stringent regulations.

Bargaining power of buyers: The bargaining power of buyers is moderate as there are several vendors providing treatment options for cardiac conditions. However, specialized medical care and expertise required provide some differentiation.

Bargaining power of suppliers: The bargaining power of suppliers is low due to the availability of substitute components. However, specialized enzymes and drug development capabilities increase reliance on few suppliers.

Threat of new substitutes: Alternate non-invasive procedures pose minimal threat due to efficiency and proven efficacy of fibrinolytic therapy.

Competitive rivalry: High due to presence of many global and local vendors.

SWOT Analysis

Strength: Established efficacy and safety profiles of available drugs. Large patient pool suffering from cardiac conditions globally.
Weakness: Short treatment windows requiring quick diagnostic and administration. Stringent regulatory approvals and recalls impact business.
Opportunity: Rise in cardiovascular diseases due to changing lifestyle and demographics in emerging nations. New drug delivery systems and combination therapies.
Threats: Price controls and pressure to reduce healthcare expenditures. Patent cliffs of blockbuster drugs.

Read Our More Blogs : https://makuv.com/catheter-directed-fibrinolytic-therapy-is-fastest-growing-segment-fueling-the-growth-of-fibrinolytic-therapy-market/